Penghui Liu – InmunoES

FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort

29 de September de 2026 by Penghui Liu

ObjectiveTo compare FLOT and SOX as chemotherapy backbones for neoadjuvant or conversion immunochemotherapy in gastric cancer, with emphasis on pathological efficacy, treatment-related toxicity, treatment feasibility, postoperative safety, and explorat…

Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects

26 de February de 2026 by Penghui Liu

Gastric cancer is among the most prevalent malignant tumors of the digestive system worldwide. In recent years, immune checkpoint inhibitors (ICIs) have achieved substantial advances in the treatment of gastric cancer. By blocking the PD-1/PD-L1 and CT…

Pathologic response and safety of preoperative treatment regimens in gastric cancer undergoing D2 gastrectomy: a real-world cohort study

29 de January de 2026 by Penghui Liu

ObjectiveTo compare pathological response and safety among three preoperative treatment regimens—chemotherapy alone, chemotherapy plus immunotherapy, and chemotherapy plus immunotherapy and targeted therapy—in gastric cancer undergoing D2 gastrectomy, …